Trial · NCT02489344
Results by group453
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 453
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | GZ/SAR402671 | 9 | Participants | ||
| Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematological Parameters | GZ/SAR402671 | Hemoglobin <=115 g/L | 1 | Participants | |
| Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematological Parameters | GZ/SAR402671 | Hemoglobin >=185 g/L | 0 | Participants | |
| Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematological Parameters | GZ/SAR402671 | Hemoglobin DFB >=20 g/L | 0 | Participants | |
| Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematological Parameters | GZ/SAR402671 | Hematocrit <=0.37 v/v | 6 | Participants | |
| Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematological Parameters | GZ/SAR402671 | Hematocrit >0.55 v/v | 0 | Participants | |
| Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematological Parameters | GZ/SAR402671 | Erythrocytes: >=6 Tera/L | 0 | Participants | |
| Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematological Parameters | GZ/SAR402671 | Platelets <100 Giga/L | 0 | Participants | |
| Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematological Parameters | GZ/SAR402671 | Platelets >=700 Giga/L | 0 | Participants | |
| Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematological Parameters | GZ/SAR402671 | Leukocytes <3.0 Giga/L (NB) or <2.0 Giga/L (B) | 0 | Participants | |
| Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematological Parameters | GZ/SAR402671 | Leukocytes >=16.0 Giga/L | 0 | Participants | |
| Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematological Parameters | GZ/SAR402671 | Neutrophils <1.5 Giga/L (NB) or <1.0 Giga/L (B) | 0 | Participants | |
| Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematological Parameters | GZ/SAR402671 | Lymphocytes >4.0 Giga/L | 0 | Participants | |
| Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematological Parameters | GZ/SAR402671 | Monocytes >0.7 Giga/L | 2 | Participants | |
| Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematological Parameters | GZ/SAR402671 | Basophils >0.1 Giga/L | 1 | Participants | |
| Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematological Parameters | GZ/SAR402671 | Eosinophils >0.5 Giga/L or >ULN (ULN >=0.5 Giga/L) | 0 | Participants | |
| Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Electrolytes | GZ/SAR402671 | Sodium <=129 mmol/L | 0 | Participants | |
| Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Electrolytes | GZ/SAR402671 | Sodium >=160 mmol/L | 0 | Participants | |
| Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Electrolytes | GZ/SAR402671 | Potassium <3 mmol/L | 0 | Participants | |
| Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Electrolytes | GZ/SAR402671 | Potassium >=5.5 mmol/L | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02489344/results